- Malvern Scientists to Present Emerging Protein Characterization Techniques at Biotherapeutics Analytical Summit
Industry News: Malvern Scientists to Present Emerging Protein Characterization Techniques at Biotherapeutics Analytical SummitDr Wei Qi and Dr Linda Kidder, both senior scientists within Malvern Instruments’ Bioscience Development Initiative, will present work on techniques for protein analysis at the 2014 Biotherapeutics Analytical Summit which takes place in Baltimore MD, USA, from 24-27 March.
The topic of Dr Wei Qi’s poster is ‘Emerging Techniques for Therapeutic Protein Characterization - Viscosity, Stability and Sub-Visible Particles
’ while Dr Linda Kidder’s oral presentation on 25 March will discuss ‘Improved Understanding of Association Between Protein Colloidal and Conformation Stability with Combined DLS/Raman’
. A novel approach to protein therapeutics characterization
Dr Kidder will describe how the combination of dynamic light scattering (DLS) and Raman spectroscopy presents a novel approach to protein therapeutics characterization. It enables the simultaneous characterization of protein secondary and tertiary structure, as well as hydrodynamic size, even at high concentrations (> 50 mg/mL), thus enabling the link between colloidal and conformational stability to be more fully understood. She will show some of the new insights and observations that can be gained by applying DLS/Raman to actual biopharmaceutical formulations. Biopharmaceutical development products on display
Malvern is also pleased to be a sponsor for the summit and will present instruments from the company’s fast-growing analytical toolkit for biopharmaceutical development applications as part of its exhibit on Booth #6. This toolkit encompasses tried and trusted solutions such as Viscotek size exclusion chromatographs to assess product purity and the Zetasizer range for sizing and zeta potential analysis for product stability, as well as groundbreaking new technologies. The Viscosizer 200, for example, is used to assess bioformulation suitability and stability as early as late stage discovery and sits alongside Archimedes and the Nanosight range of Nanoparticle Tracking Analysis instruments to quantify early aggregation in bioformulations.